You have 9 free searches left this month | for more free features.

Omacetaxine

Showing 1 - 23 of 23

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

High Grade MDS Trial in Aurora (Omacetaxine, Azacitidine)

Recruiting
  • High Grade Myelodysplastic Syndromes
  • Aurora, Colorado
    Universtiy of Colorado Denver
Nov 17, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Relapsed or Refractory Hematologic Malignancies Trial in Chicago (Omacetaxine, Venetoclax)

Recruiting
  • Relapsed or Refractory Hematologic Malignancies
  • Chicago, Illinois
    University of Illinois Cancer Center
Sep 27, 2022

Acute Myeloid Leukemia Trial in NanJing (Homoharringtonine, Azacitidine)

Recruiting
  • Acute Myeloid Leukemia
  • NanJing, China
    Department of Hematology, Zhongda Hospital, Medical School of So
Sep 2, 2022

Acute Myeloid Leukemia Trial in Chicago (Cytarabine, Idarubicin, Omacetaxine mepesuccinate)

Terminated
  • Acute Myeloid Leukemia
  • Chicago, Illinois
    University of Illinois at Chicago
Jul 1, 2021

Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

Terminated
  • Chronic Myeloid Leukemia
  • Omacetaxine mepesuccinate
  • Jacksonville, Florida
  • +9 more
Nov 6, 2021

Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

Completed
  • Chronic Myeloid Leukemia
  • Omacetaxine mepesuccinate
  • Los Angeles, California
  • +28 more
Dec 1, 2021

Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

Completed
  • Chronic Myeloid Leukemia
  • Omacetaxine mepesuccinate
  • Los Angeles, California
  • +31 more
Nov 11, 2021

AML, FLT3-ITD Mutation Trial in Hong Kong (Quizartinib, Omacetaxine Mepesuccinate Injection)

Unknown status
  • AML
  • FLT3-ITD Mutation
  • Hong Kong, Hong Kong
    The University of Hong Kong
Dec 9, 2020

AML, FLT3-ITD Mutation Trial in Hong Kong (Sorafenib, Omacetaxine Mepesuccinate Injection)

Completed
  • AML
  • FLT3-ITD Mutation
  • Hong Kong, Hong Kong
    The University of Hong Kong
Mar 26, 2020

Acute Myelogenous Leukemia (AML) Trial in Atlanta (Omacetaxine)

Terminated
  • Acute Myelogenous Leukemia (AML)
  • Omacetaxine
  • Atlanta, Georgia
    Emory University Winship Cancer Institute
Sep 5, 2019

Cancer Target Therapy Efficacy

Active, not recruiting
  • Cancer
  • RNA sequencing
  • +5 more
  • Walnut, California
  • +6 more
Sep 13, 2021

Leukemia Trial in Houston (Omacetaxine, Cytarabine)

Completed
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Apr 30, 2018

Leukemia Trial in Houston (Omacetaxine, Decitabine)

Terminated
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 9, 2018

MDS Trial in Gainesville (Omacetaxine, Azacitidine, G-CSF)

Withdrawn
  • Myelodysplastic Syndromes
  • Omacetaxine
  • +2 more
  • Gainesville, Florida
    University of Florida Health Shands Cancer Hospital
May 1, 2017

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia

Terminated
  • Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
  • +16 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Apr 5, 2016

Hematologic Malignancies, Solid Tumors Trial in Amsterdam (omacetaxine mepesuccinate)

Completed
  • Hematologic Malignancies
  • Solid Tumors
  • omacetaxine mepesuccinate
  • Amsterdam, Netherlands
    Teva Investigational Site 38045
Jan 29, 2015

Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase Trial in Houston (Homoharringtonine,

Terminated
  • Myeloid Leukemia, Chronic
  • +3 more
  • Houston, Texas
    Univ. of Texas M.D. Anderson Cancer Center
Jan 8, 2015

Hematologic Tumors Trial in Dallas (Omacetaxine)

Completed
  • Hematologic Tumors
  • Omacetaxine
  • Dallas, Texas
    Mary Crowley Cancer Research Center
May 9, 2014

Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia Trial in Boston (omacetaxine

Completed
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Chronic Phase Chronic Myelogenous Leukemia
  • omacetaxine mepesuccinate
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Harvard Cancer Center
Jun 4, 2013

Leukemia Trial in Boston, Houston (recombinant interferon alfa, omacetaxine mepesuccinate)

Completed
  • Leukemia
  • recombinant interferon alfa
  • omacetaxine mepesuccinate
  • Boston, Massachusetts
  • +1 more
Feb 4, 2013

Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous

Completed
  • Childhood Chronic Myelogenous Leukemia
  • +3 more
  • omacetaxine mepesuccinate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 22, 2013

Leukemia Trial in Houston (Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate)

Completed
  • Leukemia
  • Recombinant Interferon Alfa
  • +2 more
  • Houston, Texas
    University of Texas - MD Anderson Cancer Center
Jul 27, 2012